Revascularisation of coronary artery disease in patients with diabetes mellitus

Swiss Medical Weekly

Volumn 139, Issue 45-46, 2009, Pages 654-664

  Cook, Stéphane ^a   Windecker, Stephan ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Coronary artery bypass grafting (CABG); Coronary artery disease; Diabetes mellitus; Percutaneous coronary intervention (PCI)

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; PRASUGREL; RAPAMYCIN; TIROFIBAN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANATOMICAL VARIATION; BARE METAL STENT; CARDIOGENIC SHOCK; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG ELUTING STENT; ENDOTHELIAL DYSFUNCTION; FOLLOW UP; GRAFT FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART SURGERY; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREVALENCE; REPEAT PROCEDURE; REVASCULARIZATION; REVIEW; ST SEGMENT ELEVATION; STABLE ANGINA PECTORIS; STROKE; SURVIVAL; UNSTABLE ANGINA PECTORIS;

EID: 70449657667     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Seidell JC. Obesity, insulin resistance and diabetes - a world-wide epidemic. Br J Nutr. 2000:S5-8.
2. Kopelman PG, Hitman GA. Diabetes. Exploding type II. Lancet. 1998;352(Suppl 4):SIV5.
3. Cook S, Scherrer U. Insulin resistance, a new target for nitric oxide-delivery drugs. Fundam Clin Pharmacol. 2002;16: 441-453 (Pubitemid 35463880)
4. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;14(Suppl 5):S1-85.
5. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 2004; 93:136-141 (Pubitemid 38058719)
6. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-1431
7. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of Obesity, Diabetes, and Obesity- Related Health Risk Factors, 2001. JAMA. 2003;289:76-79
8. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053
9. Cook S. Coronary artery disease, nitric oxide and oxidative stress: the "Yin-Yang" effect - a Chinese concept for a world-wide pandemic. Swiss Med Wkly. 2006;136:103-113
10. Cook S, Windecker S. Surgical versus percutaneous revascularization of coronary artery disease in diabetic patients. Best Practice & Research Clinical Endocrinology & Metabolism. 2009;2:1-18.
11. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction. N Engl J Med. 1998;339:229-234 (Pubitemid 28350165)
12. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ., 2000;321:405-412 (Pubitemid 30609442)
13. Group DS, and on behalf of the European Diabetes Epidemiology, Glucose Tolerance and Cardiovascular Mortality: Comparison of Fasting and 2-Hour Diagnostic Criteria. Arch Intern Med. 2001;161:397-405.
14. Hurni CA, Perret S, Monbaron D, Gaillard R, Ruiz J. Coronary artery disease screening in diabetic patients: how good is guideline adherence? Swiss Med Wkly. 2007;137:199-204.
15. Stein B, Weintraub WS, Gebhart S, Cohen-Bernstein CL, Grosswald R, Liberman HA, et al. Influence of Diabetes Mellitus on Early and Late Outcome After Percutaneous Transluminal Coronary Angioplasty. Circulation. 1995;91:979-989
16. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary Angioplasty in Diabetic Patients: The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation. 1996;94:1818-1825
17. Van Belle E, Ketelers R, Bauters C, Perie M, Abolmaali K, Richard F, et al. Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: A key determinant of survival in diabetics after coronary balloon angioplasty. Circulation. 2001;103:1218-1224 (Pubitemid 32221343)
18. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S, et al. Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice: 4-Year Results From a Large 2-Institutional Cohort Study. J Am Coll Cardiol. 2008;52:1134-1140
19. Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schomig A, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ. 2008;337:a1331.
20. Cook S, Meier B, Windecker S. Sirolimus-eluting versus pacli-taxel- eluting stents: are there differences in reality? Cardiol Internat. 2007 Spring: 19-25.
21. Cox D, Lasala JM. Two Two-year Clinical Outcomes Following year Clinical Outcomes Following Paclitaxel Paclitaxel-eluting Stent Implantation in eluting Stent Implantation in Patients with Diabetes Patients with Diabetes. EuroIntervention. 2008. EuroPCR - Barcelona: Late breaking trials.
22. Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007;357:1393-1402 (Pubitemid 47541971)
23. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, Gomez-Hospital JA, Alfonso F, Hernandez-Antolin R, et al. Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. Circulation. 2005;112:2175-2183
24. Baumgart D, Klauss V, Baer F, Hartmann F, Drexler H, Motz W, et al. One-Year Results of the SCORPIUS Study: A German Multicenter Investigation on the Effectiveness of Sirolimus-Eluting Stents in Diabetic Patients. J Am Coll Cardiol. 2007;50:1627-1634 (Pubitemid 47562680)
25. Cook S, Meier B. Have we been misled by the ESC DES firestorm? EuroIntervention. 2008;3:535-537
26. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A Pooled Analysis of Data Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. N Engl J Med. 2007;356:989-997 (Pubitemid 46376799)
27. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al. Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. N Engl J Med. 2007;356: 1030-1039 (Pubitemid 46376803)
28. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schoemig A, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-948 (Pubitemid 47393576)
29. Briguori C. Novel Approaches for Preventing or Limiting Events (NAPLES) II Trial. Presented at: American College of Cardiology Scientific Session/ i2 Summit. March 30, 2009; Orlando, FL
30. Lee SW. A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetes Patients: Two-Year Clinical Outcomes of DECLARE Diabetes Trial. TCT, 2008: Late- Breaking Trials.
31. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015 (Pubitemid 350106708)
32. Carson JL, Scholz PM, Chen AY, Peterson ED, Gold J, Schneider SH. Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. J Am Coll Cardiol. 2002;40:418-423 (Pubitemid 34833154)
33. Mohammadi S, Dagenais F, Mathieu P, Kingma JG, Doyle D, Lopez S, et al. Long-Term Impact of Diabetes and Its Comorbidities in Patients Undergoing Isolated Primary Coronary Artery Bypass Graft Surgery. Circulation. 2007;116:I-220-225
34. Leavitt BJ, Sheppard L, Maloney C, Clough RA, Braxton JH, Charlesworth DC, et al. Effect of Diabetes and Associated Conditions on Long-Term Survival After Coronary Artery Bypass Graft Surgery. Circulation. 2004;110:II-41-44
35. Tatoulis J, Buxton BF, Fuller JA. Patencies of 2127 arterial to coronary conduits over 15 years. The Annals of Thoracic Surgery. 2004;77:93-101. (Pubitemid 38129992)
36. Stevens LM, Carrier M, Perrault LP, Hebert Y, Cartier R, Bouchard D, et al. Influence of diabetes and bilateral internal thoracic artery grafts on long-term outcome for multivessel coronary artery bypass grafting. Eur J Cardiothorac Surg. 2005;27:281-288
37. Choudhary BP, Antoniades C, Brading AF, Galione A, Channon K, Taggart DP. Diabetes Mellitus as a Predictor for Radial Artery Vasoreactivity in Patients Undergoing Coronary Artery Bypass Grafting. J Am Coll Cardiol. 2007;50:1047-1053
38. de Jaegere PPT, Suyker WJL. Off-pump coronary artery by-pass surgery. Heart. 2002;88:313-318
39. Flaherty JD, Davidson CJ. Diabetes and Coronary Revascularization. JAMA. 2005;293:1501-1508
40. Bravata DM, Gienger AL, McDonald KM, Sundaram V, Perez MV, Varghese R, et al. Systematic review: the comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. Ann Intern Med. 2007; 147:703-716
41. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med. 1996;335:217-225
42. Investigators TB. Influence of Diabetes on 5-Year Mortality and Morbidity in a Randomized Trial Comparing CABG and PTCA in Patients With Multivessel Disease: The Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 1997;96:1761-1769
43. Henderson RA, Pocock SJ, Sharp SJ, Nanchahal K, Sculpher MJ, Buxton MJ, et al. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary- artery bypass grafting. Randomised Intervention Treatment of Angina. Lancet. 1998;352:1419-1425
44. King SB, Lembo NJ, Weintraub WS, Kosinski AS, Barnhart HX, Kutner MH, et al. A Randomized Trial Comparing Coronary Angioplasty with Coronary Bypass Surgery. N Engl J Med. 1994;331:1044-1050 (Pubitemid 24317696)
45. CABRI Trial Participants, First-year results of CABRI. Lancet. 1995;346:1179-1184
46. Serruys PW, De Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489-495
47. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331:496-501.
48. Sedlis SP, Morrison DA, Lorin JD, Esposito R, Sethi G, Sacks J, et al. Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. J Am Coll Cardiol. 2002;40:1555-1566 (Pubitemid 35253632)
49. Serruys PW, Ong ATL, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJRM, et al. Five-Year Outcomes After Coronary Stenting Versus Bypass Surgery for the Treatment of Multivessel Disease: The Final Analysis of the ARTS Randomized Trial. J Am Coll Cardiol. 2005. 46: 575-581
50. Booth J, Clayton T, Pepper J, Nugara F, Flather M, Sigwart U, et al. Randomized, Controlled Trial of Coronary Artery Bypass Surgery Versus Percutaneous Coronary Intervention in Patients With Multivessel Coronary Artery Disease: Six-Year Follow-Up From the Stent or Surgery Trial. Circulation. 2008;118:381-388
51. Rodriguez AE, Baldi J, Pereira CFN, Navia J, Alemparte M, Delacasa A, et al. Five-Year Follow-Up of the Argentine Randomized Trial of Coronary Angioplasty With Stenting Versus Coronary Bypass Surgery in Patients With Multiple Vessel Disease (ERACI II). J Am Coll Cardiol. 2005;46:582-588 (Pubitemid 41132681)
52. Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LAC, Jatene FB, et al. Five-Year Follow-Up of the Medicine, Angioplasty, or Surgery Study (MASS II): A Randomized Controlled Clinical Trial of 3 Therapeutic Strategies for Multivessel Coronary Artery Disease. Circulation. 2007;115:1082-1089 (Pubitemid 46673170)
53. Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet. 373:1190-1197
54. Mercado N, Wijns W, Serruys PW, Sigwart U, Flather MD, Stables RH, et al. One-year outcomes of coronary artery by-pass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: A meta-analysis of individual patient data from randomized clinical trials. J Thorac Cardiovasc Surg. 2005;130:512-519
55. Daemen J, Boersma E, Flather M, Booth J, Stables R, Rodriguez A, et al. Long-Term Safety and Efficacy of Percutaneous Coronary Intervention With Stenting and Coronary Artery Bypass Surgery for Multivessel Coronary Artery Disease: A Meta-Analysis With 5-Year Patient-Level Data From the ARTS, ERACI-II, MASS-II, and SoS Trials. Circulation. 2008;118:1146-1154
56. Tarantini G, Ramondo A, Napodano M, Favaretto E, Gardin A, Bilato C, et al. PCI versus CABG for multivessel coronary disease in diabetics. Catheter Cardiovasc Interv. 2009;73:50-58
57. Serruys P. What Have We Learned from ARTS I and ARTS II? AHA, Special Session, November 4th, 2007. CVS.73. AHA/ESC Joint Session: Multivessel Coronary Artery Disease - Stents vs CABG: Room W415a.
58. Serruys PW, Colombo A, Morice MC, Ong ATL, Hamm C, de Bruyne B, et al. Arterial Revascularisation Therapies Study Part II - Sirolimus-eluting stents for the treatment of patients with multivessel de novocoronary artery lesions. EuroIntervention. 2005;1:147-156
59. Rodriguez AE, Maree AO, Mieres J, Berrocal D, Grinfeld L, Fernandez-Pereira C, et al. Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry. Eur Heart J. 2007;28:2118-2125 (Pubitemid 47517450)
60. Yang JH, Gwon H-C, Cho SJ, Hahn JY, Choi J-H, Choi SH, et al. Comparison of Coronary Artery Bypass Grafting With Drug-Eluting Stent Implantation for the Treatment of Multi-vessel Coronary Artery Disease. Ann Thorac Surg. 2008; 85:65-70. (Pubitemid 350265787)
61. Javaid A, Steinberg DH, Buch AN, Corso PJ, Boyce SW, Pinto Slottow TL, et al. Outcomes of Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention With Drug- Eluting Stents for Patients With Multivessel Coronary Artery Disease. Circulation. 2007;116:I-200-206
62. Zhen KY. Coronary Artery Bypass Surgery Versus Percutaneous Coronary Intervention with Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease. J Interv Cardiology. 2007;20:10-16
63. Briguori C, Condorelli G, Airoldi F, Focaccio A, D'Andrea D, Cannavale M, et al. Comparison of Coronary Drug-Eluting Stents Versus Coronary Artery Bypass Grafting in Patients With Diabetes Mellitus. Am J Card. 2007;99:779-784
64. Lee MS, Jamal F, Kedia G, Chang G, Kapoor N, Forrester J, et al. Comparison of bypass surgery with drug eluting stents for diabetic patients with multivessel disease. Int J Card. 2007;123: 34-42. (Pubitemid 350119876)
65. Li Y, Zheng Z, Xu B, Zhang S, Li W, Gao R, et al. Comparison of Drug-Eluting Stents and Coronary Artery Bypass Surgery for the Treatment of Multivessel Coronary Disease: Three- Year Follow-Up Results From a Single Institution. Circulation. 2009;119:2040-2050
66. Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, et al. Drug-Eluting Stents vs. Coronary-Artery Bypass Grafting in Multivessel Coronary Disease. N Engl J Med. 2008;358:331-341 (Pubitemid 351159232)
67. Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, et al. Long-Term Outcomes of Coronary-Artery Bypass Grafting versus Stent Implantation. N Engl J Med. 2005; 352:2174-2183
68. Kapur A. Coronary Artery Revascularisation in Diabetes. The CARDia trial. Eur Heart J, 2008. Hotlines II. Session 1694-1695: ESC, September 1.
69. Serruys PW, Morice M-C, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. N Engl J Med. 2009;360:961-972
70. Banning AP, Westaby S, Mohr FW, Kappetein AP, Morice MC, Leadley K, et al. Revascularization With Cardiac Surgery Versus Paclitaxel-Eluting Stents in Patients With Diabetes and Metabolic Syndrome: 1-Year Results From the SYNTAX Study. i2 Summit - DES Outcomes, 2009. 2901: Saturday, March 28, 2009, 10:00 a.m. - Noon.
71. Harjai KJ, Stone GW, Boura J, Mattos L, Chandra H, Cox D, et al. Comparison of outcomes of diabetic and nondiabetic patients undergoing primary angioplasty for acute myocardial infarction. Am J Cardiol. 2003;91:1041-1045 (Pubitemid 36514916)
72. Timmer JR, Ottervanger JP, Thomas K, Hoorntje JCA, de Boer M-J, Suryapranata H, et al. Long-term, cause-specific mortality after myocardial infarction in diabetes. Eur Heart J. 2004;25:926-931 (Pubitemid 38857866)
73. Grines C, Patel A, Zijlstra F, Weaver WD, Granger C, Simes RJ, et al. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: Six-month follow up and analysis of individual patient data from randomized trials. Am Heart J. 2003;145:47-57. (Pubitemid 36034497)
74. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, et al. Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial Infarction. N Engl J Med. 2001;344:1895-1903 (Pubitemid 32553358)
75. Montalescot G, Antoniucci D, Kastrati A, Neumann FJ, Borentain M, Migliorini A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J. 2007;28:443-449 (Pubitemid 47343560)
76. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med. 1999;341:625-634
77. White HD, Assmann SF, Sanborn TA, Jacobs AK, Webb JG, Sleeper LA, et al. Comparison of Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting After Acute Myocardial Infarction Complicated by Cardiogenic Shock: Results From the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) Trial. Circulation. 2005;112:1992-2001.
78. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, et al. Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non-Q-Wave Myocardial Infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000; 102:1014-1019 (Pubitemid 30656008)
79. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segmentelevation acute coronary syndromes. Circulation. 2001; 104:2767-2771 (Pubitemid 33126648)
80. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet. 2000;356:9-16.
81. Norhammar A, Malmberg K, Diderholm E, Lagerqvist B, Lindahl B, Ryden L, et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol. 2004;43:585-591 (Pubitemid 38229530)
82. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban. N Engl J Med. 2001;344:1879-1887 (Pubitemid 32564900)
83. Stone GW, Mehran R, Dangas G, Lansky AJ, Kornowski R, Leon MB. Differential Impact on Survival of Electrocardio-graphic Q-Wave Versus Enzymatic Myocardial Infarction After Percutaneous Intervention: A Device-Specific Analysis of 7147 Patients. Circulation. 2001;104:642-647 (Pubitemid 32738516)
84. Jones RH, Kesler K, Phillips HR, Mark DB, Smith PK, Nelson CL, et al. Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. J Thorac Cardiovasc Surg. 1996;111:1013-1025 (Pubitemid 26146056)